Pharmacogenomic Effect/ADR for Tramadol (DBSNPE006631)

Identifier
DBSNPE006631
Drug
Tramadol (DB00193)
Interacting Gene/Enzyme
Cytochrome P450 2D6
Gene Name
CYP2D6
UniProt ID
P10635
Defining Change(s)
-1770G>ANot Available
-1584C>GNot Available
-1235A>GNot Available
-740C>TNot Available
-678G>ANot Available
CYP2D7 gene conversion in intron 1Not Available
310G>TNot Available
746C>GNot Available
843T>GNot Available
1661G>CNot Available
2850C>TNot Available
3384A>CNot Available
3584G>ANot Available
3790C>TNot Available
4042G>ANot Available
4180G>CNot Available
4481G>ANot Available
Allele Name
CYP2D6*31
Genotype(s)
Not Available
Type(s)
ADR Inferred Effect
Groups
Non-functional CYP2D6
Description
Poor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.
References
  1. Ultram® (tramadol hydrochloride) tablets[package insert]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; 2016. [Link]